Morgan Stanley Humacyte, Inc. Call Options Transaction History
Morgan Stanley
- $1.59 Trillion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HUMA
# of Institutions
161Shares Held
45MCall Options Held
852KPut Options Held
748K-
Vanguard Group Inc Valley Forge, PA7.52MShares$8.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.14MShares$8.43 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$3.65 Million0.0% of portfolio
-
State Street Corp Boston, MA2.41MShares$2.84 Million0.0% of portfolio
-
Ubs Group Ag2MShares$2.36 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $122M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...